Intellipharmaceutics International Inc (IPCI) 2.36 $IPCI
IntelliPharmaCeutics (IPCI) Jumps: Stock Moves 5.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 7:30AM CST
IntelliPharmaCeutics International Inc. (IPCI) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
IPCI: 2.36 (+0.06), TEVA: 56.77 (-0.58)
Intellipharmaceutics Reports the Signing of an Exclusive Licensing and Manufacturing Agreement With Teva Pharmaceuticals USA, Inc. for an Extended Release Oral Drug Product Candidate
GlobeNewswire - Mon Feb 02, 9:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has entered into an agreement with Teva Pharmaceuticals USA, Inc. ("Teva" by which the Company has granted Teva an exclusive license to market in the U.S. an extended release drug product candidate (the "product" for which Intellipharmaceutics currently has an abbreviated new drug application ("ANDA" pending for U.S. Food and Drug Administration ("FDA" approval.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
IntelliPharmaCeutics (IPCI) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:19AM CST
IntelliPharmaCeutics (IPCI) Is in Oversold Territory: What’s Next?
IPCI: 2.36 (+0.06)
Intellipharmaceutics announces Teva's launch of 5mg Focalin XR generic
M2 - Fri Nov 21, 6:02AM CST
Pharmaceutical company Intellipharmaceutics International (TSX:I) said on Thursday that Teva Pharmaceuticals has launched the generic version of the 5mg strength of its dexmethylphenidate hydrochloride generic of Focalin XR(R).
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva
GlobeNewswire - Thu Nov 20, 6:30AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company" , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that, based on information regarding recent generic introductions by Teva Pharmaceuticals ("Teva" on its website (http://www.tevagenerics.com/products/new-teva-generics), it believes that Teva has launched a generic version of the 5mg strength of its dexmethylphenidate hydrochloride generic of Focalin XR, although the exact launch date by Teva is not known by the Company.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics elects Domenic Della Penna as new CFO
M2 - Wed Nov 19, 6:29AM CST
Pharmaceutical company Intellipharmaceutics International (TSX:I) reported on Tuesday that it has appointed Domenic Della Penna as its new chief financial officer, with effect from 24 November 2014.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Announces Appointment of New Chief Financial Officer
GlobeNewswire - Tue Nov 18, 6:30AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has appointed Domenic Della Penna as its new Chief Financial Officer ("CFO" effective November 24, 2014.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification
GlobeNewswire - Mon Oct 27, 6:15AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA" has provided the Company with written notification that its Toronto, Canada manufacturing facility has received an "acceptable" classification.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)
GlobeNewswire - Wed Oct 22, 4:15PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on the progress of its Regabatin(TM) XR product development. Regabatin(TM) XR pregabalin extended release capsules are the Company's non-generic pregabalin formulations. The Company intends to present the following information arising from its Regabatin(TM) XR product development program at the upcoming American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego from Nov 2-6, 2014.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06), PFE: 34.64 (-0.23)
OTC Daily Alert Stock Watch - Intellipharmaceutics International Inc. (NASDAQ: IPCI)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
IPCI: 2.36 (+0.06)
Intellipharmaceutics posts lower Q3 2014 net loss of USD1.7m
M2 - Thu Oct 16, 7:55AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) disclosed on Wednesday its net loss of USD1.7m (USD0.07 per common share) for the three months ended 31 August 2014.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
IntellipharmaCeutics' cash burn improves modestly
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 4:06PM CDT
IPCI: 2.36 (+0.06)
IntelliPharmaCeutics beats by $0.04, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 3:55PM CDT
IPCI: 2.36 (+0.06)
Intellipharmaceutics Announces Third Quarter 2014 Results
GlobeNewswire - Wed Oct 15, 3:51PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Profound Medical Appoints Shameze Rampertab as Chief Financial Officer
GlobeNewswire - Wed Oct 15, 6:00AM CDT
Profound Medical Inc., a medical device company developing and commercializing a unique, minimally invasive treatment for prostate cancer, today announced it has named Shameze Rampertab to the position of Chief Financial Officer. Prior to this appointment, Mr. Rampertab was the VP of Finance and Chief Financial Officer of Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I).
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics reports departure of CFO Shameze Rampertab on 10 October 2014
M2 - Wed Oct 01, 6:07AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) stated on Wednesday that its vice president, Finance and chief financial officer, Shameze Rampertab, is stepping down on 10 October 2014 to pursue an opportunity in the medical devices industry.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Announces Resignation of Chief Financial Officer
GlobeNewswire - Tue Sep 30, 4:25PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Shameze Rampertab, Vice President, Finance and Chief Financial Officer, who is leaving the Company effective October 10, 2014 to pursue an opportunity in the medical devices industry.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
IntelliPharmaCeutics (IPCI) Jumps: Stock Moves 5.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 7:30AM CST
IntelliPharmaCeutics International Inc. (IPCI) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
IPCI: 2.36 (+0.06), TEVA: 56.77 (-0.58)
Intellipharmaceutics Reports the Signing of an Exclusive Licensing and Manufacturing Agreement With Teva Pharmaceuticals USA, Inc. for an Extended Release Oral Drug Product Candidate
GlobeNewswire - Mon Feb 02, 9:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has entered into an agreement with Teva Pharmaceuticals USA, Inc. ("Teva" by which the Company has granted Teva an exclusive license to market in the U.S. an extended release drug product candidate (the "product" for which Intellipharmaceutics currently has an abbreviated new drug application ("ANDA" pending for U.S. Food and Drug Administration ("FDA" approval. I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
IntelliPharmaCeutics (IPCI) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:19AM CST
IntelliPharmaCeutics (IPCI) Is in Oversold Territory: What’s Next?
IPCI: 2.36 (+0.06)
Intellipharmaceutics announces Teva's launch of 5mg Focalin XR generic
M2 - Fri Nov 21, 6:02AM CST
Pharmaceutical company Intellipharmaceutics International (TSX:I) said on Thursday that Teva Pharmaceuticals has launched the generic version of the 5mg strength of its dexmethylphenidate hydrochloride generic of Focalin XR(R).
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva
GlobeNewswire - Thu Nov 20, 6:30AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that, based on information regarding recent generic introductions by Teva Pharmaceuticals ("Teva" on its website (http://www.tevagenerics.com/products/new-teva-generics), it believes that Teva has launched a generic version of the 5mg strength of its dexmethylphenidate hydrochloride generic of Focalin XR, although the exact launch date by Teva is not known by the Company. I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics elects Domenic Della Penna as new CFO
M2 - Wed Nov 19, 6:29AM CST
Pharmaceutical company Intellipharmaceutics International (TSX:I) reported on Tuesday that it has appointed Domenic Della Penna as its new chief financial officer, with effect from 24 November 2014.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Announces Appointment of New Chief Financial Officer
GlobeNewswire - Tue Nov 18, 6:30AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has appointed Domenic Della Penna as its new Chief Financial Officer ("CFO"
effective November 24, 2014. I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification
GlobeNewswire - Mon Oct 27, 6:15AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA"
has provided the Company with written notification that its Toronto, Canada manufacturing facility has received an "acceptable" classification. I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)
GlobeNewswire - Wed Oct 22, 4:15PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on the progress of its Regabatin(TM) XR product development. Regabatin(TM) XR pregabalin extended release capsules are the Company's non-generic pregabalin formulations. The Company intends to present the following information arising from its Regabatin(TM) XR product development program at the upcoming American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego from Nov 2-6, 2014.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06), PFE: 34.64 (-0.23)
OTC Daily Alert Stock Watch - Intellipharmaceutics International Inc. (NASDAQ: IPCI)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
IPCI: 2.36 (+0.06)
Intellipharmaceutics posts lower Q3 2014 net loss of USD1.7m
M2 - Thu Oct 16, 7:55AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) disclosed on Wednesday its net loss of USD1.7m (USD0.07 per common share) for the three months ended 31 August 2014.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
IntellipharmaCeutics' cash burn improves modestly
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 4:06PM CDT
IPCI: 2.36 (+0.06)
IntelliPharmaCeutics beats by $0.04, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 3:55PM CDT
IPCI: 2.36 (+0.06)
Intellipharmaceutics Announces Third Quarter 2014 Results
GlobeNewswire - Wed Oct 15, 3:51PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Profound Medical Appoints Shameze Rampertab as Chief Financial Officer
GlobeNewswire - Wed Oct 15, 6:00AM CDT
Profound Medical Inc., a medical device company developing and commercializing a unique, minimally invasive treatment for prostate cancer, today announced it has named Shameze Rampertab to the position of Chief Financial Officer. Prior to this appointment, Mr. Rampertab was the VP of Finance and Chief Financial Officer of Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I).
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics reports departure of CFO Shameze Rampertab on 10 October 2014
M2 - Wed Oct 01, 6:07AM CDT
Pharmaceutical company Intellipharmaceutics International (TSX:I) stated on Wednesday that its vice president, Finance and chief financial officer, Shameze Rampertab, is stepping down on 10 October 2014 to pursue an opportunity in the medical devices industry.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
Intellipharmaceutics Announces Resignation of Chief Financial Officer
GlobeNewswire - Tue Sep 30, 4:25PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Shameze Rampertab, Vice President, Finance and Chief Financial Officer, who is leaving the Company effective October 10, 2014 to pursue an opportunity in the medical devices industry.
I.TO: 2.94 (+0.06), IPCI: 2.36 (+0.06)
